Director, Center for Developmental Therapeutics; Entrepreneur-in-Residence, Chemistry of Life Processes Institute; Research Professor of Molecular Biosciences; Weinberg College of Arts and Sciences; Member, Robert H. Lurie Comprehensive Cancer Center
Andrew Mazar is an experienced research director and senior manager with over 20 years of pharmaceutical and biotechnology industry experience. He has extensive expertise in translational medicine including the design, discovery and pre-clinical and clinical development of small molecules, peptides and biologics for the treatment of cancer and other angiogenesis and inflammation-dependent diseases including Crohn’s and acute and chronic lung injury/disease. His core competencies include discovery and development of cancer, pulmonary and neurodegenerative drugs and he has a strong track record of synergizing with investigators in these areas to advance investigator initiated projects. He is one of the translational “go-to” people within the Northwestern University community at large for advancing new therapeutics into pre-clinical and early clinical evaluation.
Dr. Mazar is internationally recognized for research in tumor biology, angiogenesis and the urokinase plasminogen activator system. Mazar has been an inventor on multiple issued and filed patents. He has established track record in scientific community which includes: presenting research seminars at national and international meetings; publication in peer-reviewed scientific journals; publication of invited reviews and book chapters; participation in NIH and VA study sections; and organizational roles in planning international scientific meetings. In addition, he has expertise in translating oncology drugs from discovery through proof-of-principle clinical trials; strategic assessment of external science; biotechnology licensing; intellectual property; partnership and alliance opportunities; and leading the due diligence process.